Evidence map›Paper›PMID 41427824›Full record

ArticleThe Journal of general virology2025

Broadly neutralizing human monoclonal antibodies against BK polyomavirus genotypes.

J Andrew Duty, Thomas A Kraus, Madhu Kumar, Nicolo A Tortorella, Tajudeen O Jimoh, Emma B Barrall, Diana V Pastrana, Christopher B Buck, Thomas M Moran, Domenico Tortorella

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of general virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

J Andrew DutyCenter for Therapeutic Antibody Development, Drug Discovery Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10709, USA.
Thomas A KrausDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10709, USA.
Madhu KumarCenter for Therapeutic Antibody Development, Drug Discovery Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10709, USA.
Nicolo A TortorellaCenter for Therapeutic Antibody Development, Drug Discovery Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10709, USA.
Tajudeen O JimohDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10709, USA.
Emma B BarrallDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10709, USA.
Diana V PastranaLab of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Christopher B BuckLab of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Thomas M MoranCenter for Therapeutic Antibody Development, Drug Discovery Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10709, USA.
Domenico TortorellaDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10709, USA.

Funding

Identification of human cytomegalovirus life cycle stage-specific therapeuticsR01AI139258 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI TORTORELLA, DOMENICO · 2019 to 2022
$1.6M
Optimization of novel inhibitors of human cytomegalovirusR56AI175974 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI TORTORELLA, DOMENICO · 2024 to 2024
$684k
NIAID NIH HHS R01 AI139258NIAID NIH HHS R56 AI175974
6 · The paper itself

Abstract

BK polyomavirus (BKV) causes polyomavirus-associated nephropathy (BKV-nephropathy) and polyomavirus-associated haemorrhagic cystitis following kidney transplantation and allogeneic haematopoietic stem cell transplantation. BKV strains consist of four distinct genotypes (BKV-I, -II, -III and -IV), with more than 80% of individuals seropositive for the BKV-I genotype and lower prevalences of infection or co-infection with the other genotypes. BKV-nephropathy occurs widely in immunosuppressed transplant recipients, with the recommended treatment including reduction of immunosuppressive drugs. High serum titres of BKV-neutralizing antibodies and treatment with BKV-neutralizing intravenous immunoglobulin are associated with reduced levels of BKV-DNAemia in kidney transplant recipients, suggesting anti-BKV antibodies can limit viral load. Thus, we set out to generate broadly neutralizing human mAbs against the viral protein 1 (VP1) major capsid protein of BKV genotypes I-IV using VelocImmune

Indexed as

Antibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralBK VirusPolyomavirus InfectionsAnimalsCapsid ProteinsGenotypeHumansMiceMice, TransgenicAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralCapsid ProteinsBK polyomavirus (BKV)human stem cell transplant (HST)monoclonal antibodies (mAbs)polyomavirus-associated haemorrhagic cystitis (PyVHC)polyomavirus-associated nephropathy (PyVAN)

Identifiers

PMID41427824
PMCPMC12721715

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.